Market Research on Cystic Fibrosis - Pipeline Review, H2 2016
Cystic Fibrosis - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Cystic Fibrosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects.
To access full report with TOC, please visit Cystic Fibrosis - Pipeline Review, H2 2016
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis
- The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis
- The report reviews pipeline therapeutics for Cystic Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cystic Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Cystic Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cystic Fibrosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
- Identify potential new clients or partners in the target demographic
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis
- Identify potential new clients or partners in the target demographic
- Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Actelion Ltd Alaxia SAS AlgiPharma AS AmpliPhi Biosciences Corporation Arch Biopartners, Inc. Arcturus Therapeutics, Inc. Aridis Pharmaceuticals LLC AstraZeneca Plc Bayer AG BioAegis Therapeutics, Inc. Boehringer Ingelheim GmbH Calista Therapeutics, Inc. Catabasis Pharmaceuticals, Inc. Celtaxsys, Inc. Chrysalis Pharma SAS Cilian AG Concert Pharmaceuticals, Inc. CRISPR Therapeutics CSA Biotechnologies LLC Cyclacel Pharmaceuticals, Inc. DiscoveryBiomed, Inc. Editas Medicine, Inc. Eloxx Pharmaceuticals, Ltd. Errant Gene Therapeutics, LLC Eumedica SA Galapagos NV Gilead Sciences, Inc. GlaxoSmithKline Plc Grupo Praxis Pharmaceutical SA Horizon Pharma Plc ID Pharma Co., Ltd. Immun System I.M.S. AB Insmed Incorporated Invion Limited JHL Biotech, Inc. Kamada Ltd. Kyorin Pharmaceutical Co., Ltd. La Jolla Pharmaceutical Company Lakewood-Amedex Inc Lamellar Biomedical Ltd Laurent Pharmaceuticals Inc. Mast Therapeutics, Inc. Merck & Co., Inc. Microbion Corporation Mucokinetica Ltd. Nivalis Therapeutics, Inc. Novabiotics Limited Novartis AG OSE Immunotherapeutics Paranta Biosciences Limited Parion Sciences, Inc. Pfizer Inc. Pharmaxis Limited PhaseBio Pharmaceuticals, Inc. Polyphor Ltd. Progenra, Inc. ProMetic Life Sciences Inc. ProQR Therapeutics N.V. Protalix BioTherapeutics, Inc. Proteostasis Therapeutics, Inc. PTC Therapeutics, Inc. Pulmatrix, Inc. Raptor Pharmaceutical Corp. ReveraGen BioPharma, Inc. Savara Inc. Shionogi & Co., Ltd. Shire Plc Synovo GmbH TGV-Laboratories The International Biotechnology Center (IBC) Generium Verona Pharma Plc Vertex Pharmaceuticals Incorporated Xenetic Biosciences (UK) Limited Zambon Company S.p.A.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
posted by Reportstack @ 08:27
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home